文献速递外周动脉疾病

常用血栓预防方案对外周动脉疾病血运重建后凝血酶生成的影响

The Impact of Common Thromboprophylactic Regimens on Thrombin Generation in Patients with Peripheral Artery Disease Postrevascularization.
PubMed 文献 · Ann Vasc Surg · 2026-01-06

研究前瞻性纳入56例60岁以上接受血运重建的PAD患者,用校准自动血栓图比较不同抗栓方案对凝血酶生成的影响。MAPT+DOAC显著降低凝血酶生成速率、延长滞后时间并降低峰值凝血酶,DAPT+DOAC变化较小且不显著。患者间变异大,支持个体化抗栓策略。

要点

  • MAPT+DOAC显著降低凝血酶生成速率、延长滞后时间并降低峰值凝血酶。
  • DAPT+DOAC对凝血酶生成参数的影响较小且不显著。
  • PAD患者凝血酶生成存在明显个体间变异,支持个体化抗栓。

核心结论

  • PAD患者凝血酶生成变异明显,MAPT联合DOAC产生最显著的凝血酶生成变化,支持个体化抗栓策略。

研究设计与样本

  • 术前及术后1、3、6个月采集全血,1个月样本用校准自动血栓图定量凝血酶生成参数,随访1年。
  • 按抗栓方案分层:单抗血小板(MAPT)、双抗血小板(DAPT)、MAPT+直接口服抗凝药(DOAC)、DAPT+DOAC。

主要发现

  • MAPT+DOAC组凝血酶生成速率降低38.2 nM/min(P=0.014),滞后时间延长5.4 min(P=0.019),峰值凝血酶降低111 nM(P=0.013)。
  • DAPT+DOAC组凝血酶生成参数降低幅度较小且无统计学显著性。
  • 1年不良事件发生率:DAPT组38.5%,DAPT+DOAC组20.0%,MAPT+DOAC组17.6%,MAPT组0%。
  • 各参数标准差较大,提示患者间生物学反应异质性明显。

临床怎么用

  • 对血运重建后PAD患者,MAPT联合DOAC可显著抑制凝血酶生成,但需结合个体出血风险选择。
  • DAPT联合DOAC对凝血酶生成的抑制较弱,临床决策应综合评估获益与风险。

局限性

  • 样本量较小(56例),1年不良事件数据仅为描述性,未报告统计学比较。
  • 凝血酶生成参数标准差大,个体间变异明显,结果解释需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antithrombotic therapy reduces thrombotic risk in patients with peripheral artery disease (PAD) by targeting thrombin generation, a key hypercoagulability factor. However, the specific effects of different antithrombotic combinations on thrombin generation dynamics remain poorly understood. This study uses calibrated automated thrombogram (CAT) to objectively measure and compare patient responses to various common thromboprophylactic regimens. METHODS: We prospectively enrolled patients with PAD aged 60+ years who underwent revascularization between January 2021 and December 2022. Whole blood samples were collected preoperatively and at 1, 3, and 6 months postintervention, with 1-year clinical follow-up. Analysis focused on 1-month samples using CAT to quantify thrombin generation parameters: lag time, peak thrombin concentration, endogenous thrombin potential, and thrombin generation rate. Patients were stratified by antithrombotic regimen: mono antiplatelet therapy (MAPT), dual antiplatelet therapy (DAPT), MAPT + direct oral anticoagulant (DOAC), and DAPT + DOAC. Statistical analysis used Mann-Whitney U and t-tests. RESULTS: Among 56 PAD patients analyzed, DOAC addition produced notable thrombin generation changes, with more pronounced effects in patients on MAPT. MAPT + DOAC showed significant reductions in thrombin generation rate (-38.2 nM/min, P = 0.014), increased lag time (+5.4 min, P = 0.019), and decreased peak thrombin (-111 nM, P = 0.013). DAPT + DOAC produced smaller, nonsignificant reductions. One-year adverse events occurred in 38.5% of DAPT patients, 20.0% DAPT + DOAC, 17.6% MAPT + DOAC, and 0% MAPT patients. Large standard deviations indicated substantial interpatient variability. CONCLUSION: PAD patients demonstrate marked thrombin generation variability, with DOAC addition to MAPT producing the most significant thrombin generation changes. These findings highlight biological response heterogeneity in PAD and support individualized antithrombotic strategies.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Bucha S, Cieri IF, Rodriguez AA, et al. The Impact of Common Thromboprophylactic Regimens on Thrombin Generation in Patients with Peripheral Artery Disease Postrevascularization. Ann Vasc Surg. 2026. PMID: 41506341. doi:10.1016/j.avsg.2025.12.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。